Form 4: BioMarin CEO Reports Stock Transactions

BioMarin Pharmaceutical CEO Alexander Hardy reported recent stock acquisitions through an ESPP and subsequent dispositions, adjusting his direct beneficial ownership.

Summary

• Alexander Hardy, BioMarin Pharmaceutical Inc.'s Chief Executive Officer and a Director, reported changes in his beneficial ownership of common stock.
• On April 30, 2025, Hardy acquired 375 shares of common stock at a price of $54.137 per share through the issuer's Employee Stock Purchase Plan (ESPP).
• Following this acquisition, his direct beneficial ownership increased to 175,958 shares.
• On December 1, 2025, Hardy disposed of 16,570 shares of common stock at a price of $55.03 per share.
• This disposition resulted in his direct beneficial ownership decreasing to 159,388 shares.
• The disposition transaction code 'F' typically indicates a withholding of shares for tax purposes upon the vesting or exercise of equity awards.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual report of insider stock transactions, which are standard disclosures and do not inherently indicate positive or negative company performance.

Positives

• The acquisition of 375 shares through the Employee Stock Purchase Plan (ESPP) demonstrates continued participation by the CEO in the company's equity programs, aligning his interests with shareholders.

Negatives

• The disposition of 16,570 shares, while potentially for tax purposes, represents a reduction in the CEO's direct beneficial ownership of the company's common stock.

Future Outlook

This filing is a factual report of insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, such as those reported in a Form 4, are routine disclosures in the biotechnology and pharmaceutical industry. They provide transparency into management's direct equity holdings and changes, which can be a factor in investor sentiment, though these specific transactions appear to be standard for an executive.

Stakeholder Impact

• Shareholders: Provides transparency into the CEO's direct equity holdings and changes, which can influence investor confidence, though these transactions appear routine.
• Employees: The Employee Stock Purchase Plan (ESPP) acquisition highlights a common employee benefit program.

Key Dates

Keywords

BMRN, BioMarin Pharmaceutical, Alexander Hardy, CEO, Insider Transaction, Form 4, Stock Purchase Plan, Equity, Common Stock